Helix BioMedix, a Bothell, WA-based developer of peptide molecules, said it has raised $3.2 million through debt that can convert into shares of stock, plus warrants to buy its stock. The company (OTCBB: [[ticker:HXBM]]) plans to use the money for general corporate purposes, and to continue expanding its consumer program. The company’s peptides can be found in skin care and other cosmetic products.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
